France vs IDA blend: Access to anti-retroviral drugs, male
France
89.0%
in 2022
IDA blend
74.0%
in 2024
France rank
17th
IDA blend rank
14th
Access to anti-retroviral drugs, male over time
- France
- IDA blend
How they compare
France currently reports 89.0% against 74.0% in IDA blend, a difference of 15.0%.
That makes France's figure about 1.2 times IDA blend's.
Across all 23 years both countries report, France has been ahead every year.
France ranks 17th and IDA blend ranks 14th of 141 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | France | IDA blend | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 79.8% | 5.5% | 74.3% | France |
| 2010s | 86.9% | 38.5% | 48.4% | France |
| 2020s | 88.7% | 64.6% | 24.1% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, France or IDA blend?
- France, at 89.0% against 74.0% in IDA blend as of 2022.
- What is the difference in access to anti-retroviral drugs, male between France and IDA blend?
- 15.0%, with France ahead.
- How many years of comparable data are there for France and IDA blend?
- 23 years are reported by both, from 2000 to 2022.
- How do France and IDA blend rank globally for access to anti-retroviral drugs, male?
- France ranks 17th and IDA blend ranks 14th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.